Lupin Launches Authorised Generic of Ravicti® in the US

Global pharmaceutical company Lupin Limited has announced the launch of an authorized generic version of Ravicti® (Glycerol Phenylbutyrate) Oral Liquid, 1.1g/mL, in the United States. This launch strengthens Lupin’s presence in the US specialty pharmaceutical market and provides patients with a more accessible treatment option.

Treatment for Urea Cycle Disorders

Ravicti® Oral Liquid, 1.1g/mL, is indicated for the chronic management of urea cycle disorders (UCDs). UCDs are rare genetic conditions that impair the body’s ability to remove ammonia from the blood, leading to serious health complications. This formulation is specifically designed for patients who cannot be managed through dietary protein restriction or amino acid supplementation alone, offering an effective solution for long-term care.

Authorised Generic Benefits

An authorised generic is chemically identical to its branded counterpart but marketed under its chemical name. The introduction of this version by Lupin provides patients and healthcare providers with a cost-effective alternative without compromising on efficacy, safety, or quality. This launch reflects Lupin’s commitment to improving access to essential therapies and supporting the US healthcare system.

Strategic Significance

This move aligns with Lupin’s broader strategy to expand its specialty pharmaceutical portfolio and leverage its expertise in complex formulations. It also enhances Lupin’s competitive position in the US market by offering high-value, niche therapies to patients with rare conditions.

Lupin Share Price Performance

On October 24, 2025, Lupin share price opened at ₹1,941.90, touching the day’s low at ₹1,929.40, as of 10:43 AM on the NSE.

Also Read: Lupin Shares Rose 4% Following Plans for Major U.S. Manufacturing Facility! 

Conclusion

Lupin’s launch of the authorized generic Ravicti® Oral Liquid, 1.1g/mL, marks a significant step in expanding treatment options for patients with urea cycle disorders in the US. The development reinforces the company’s focus on accessibility, quality, and long-term patient care.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.